Kite, Arcellx announce advances in Anito-Cel Multiple Myeloma Program Ruchika Sharma12 May 2024 10:00 AM ISTRedwood City: Kite, a Gilead Company, and Arcellx, Inc. have announced several key operational updates on their partnered anitocabtagene...
USFDA approves label update for Kite's Yescarta CAR T-Cell Therapy to include overall survival data Ruchika Sharma26 Dec 2023 12:00 PM ISTSanta Monica: Kite, a Gilead Company has announced that the U.S. Food and Drug Administration (FDA), has approved a label update for Yescarta...
Gilead's Kite, Epic Bio collaborate for development of new cancer therapies Ruchika Sharma2 Nov 2023 10:00 AM ISTUnder the terms of the agreement, Epic Bio will develop constructs for Kite-selected targets for use in CAR T-cell therapies directed to blood...
Gilead Kite declares positive trial results of T-cell Therapy Yescarta in Relapsed/Refractory Large B-cell Lymphoma Ruchika Sharma19 Sept 2023 1:30 PM ISTSanta Monica: Kite, a Gilead Company has announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group...
Kite announces completion of marketing authorization transfer for Yescarta CAR T-cell therapy in Japan Ruchika Sharma25 Jun 2023 2:30 PM ISTSanta Monica: Kite Pharma, Inc., a Gilead Company, has announced that the Marketing Authorization in Japan for Yescarta (axicabtagene...
Gilead Sciences' Kite completes acquisition of Tmunity Ruchika Sharma26 Feb 2023 11:30 AM ISTSanta Monica: Kite, a Gilead Company has announced the completion of the previously announced transaction to acquire Tmunity Therapeutics, a...
USFDA approves Kite retroviral vector manufacturing facility in Southern California for commercial production Ruchika Sharma5 Oct 2022 12:52 PM ISTThe Oceanside site is part of Kite’s global commercial manufacturing network that includes facilities in El Segundo, California, Amsterdam,...
Gilead Sciences' Kite gets European Commission nod for CAR T-cell therapy Tecartus Ruchika Sharma8 Sept 2022 4:00 PM ISTSanta Monica, Calif.: Kite, a Gilead Company has announced that the European Commission (EC) has approved its CAR T-cell therapy Tecartus...
Kite gets USFDA nod for new CAR T-cell therapy site in Maryland Ruchika Sharma20 April 2022 1:12 PM ISTSanta Monica: Kite, a Gilead Company has announced the U.S. Food and Drug Administration (USFDA) has approved commercial production at the company's...
BioNTech to buy Kite Gaithersburg manufacturing facility, Neoantigen TCR cell therapy RnD platform Ruchika Sharma20 July 2021 9:00 AM ISTGermany: BioNTech SE and Kite, a Gilead Company have recently announced that the two companies have entered into a purchase agreement...
Gilead, Kite and oNKo-innate collaborate to Discover Cancer Immunotherapies Focused on NK Cells Medical Dialogues Bureau25 April 2020 10:00 AM ISTAustralia - Gilead Sciences, Inc., Kite, a Gilead Company, and oNKo-innate announced the companies have entered into a three-year cancer...
